Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Pancreatic Diseases

In brief

Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.

Key facts

Study ID

NCT06861010

Run by

Tanta University

People needed

44

Starts

2025-03-01

Expected to finish

2026-12-20

Last updated by the study team

2026-03-13

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age more than 18 years old.
• Gender: Males and Females
• Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.
• Blood amylase and lipase levels before ERCP are within the normal limits.

You may not qualify if…

• Age of less than18 years.
• Uncontrolled diabetes mellitus (DM)
• Severe bleeding tendency
• Impaired renal function (serum creatinine > 2 mg/dL), (creatinine clearance <30 ml/min)
• Patients with severe heart disease.
• Subjects who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct.
• Currently pregnant or nursing
• Admission due to established pancreatitis before ECRP
• Unwillingness to undergo ERCP.
• Previously documented allergy to ondansetron.

Where it is running

• Tanta Unuversity — Tanta, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.